Christophe Moreno
Université libre de Bruxelles
281 Papers
1.9K Citations
Christophe Moreno is an academic researcher from Université libre de Bruxelles. The author has contributed to research in topics: Medicine & Hepatitis C. The author has an hindex of 53, co-authored 259 publications. Previous affiliations of Christophe Moreno include Free University of Brussels & University of Toronto.
Chat about Author
Papers
•Journal Article
The disease burden of hepatitis C in Belgium: development of a realistic disease control strategy.
Peter Stärkel,Dominique Vandijck,Wim Laleman,P. Van Damme,Christophe Moreno,S. J. Hindman,Homie Razavi,H. Van Vlierberghe +7 more
TL;DR: Considering the evolving burden of HCV disease and the need for efficacious usage of healthcare resources, primary application of new DAAs in Belgium should focus on patients with significant and advanced fibrosis (F2-F4), providing these new drugs without delay upon availability and increasing access to therapy.
6
Hcv burden in europe: impact of national treatment practices on future hcv-related morbidity and mortality through a modeling approach
S Deuffic-Burban,Pierre Deltenre,Maria Buti,Tommaso Stroffolini,J Parkes,N Muehlberger,Uwe Siebert,Christophe Moreno,Angelos Hatzakis,William Rosenberg,S. Zeuzem,Philippe Mathurin +11 more
- 01 Oct 2010
6
External Validation of the Nomogram for Individualized Prediction of Hepatocellular Carcinoma Occurrence in Patients With Hepatitis C Virus-Related Compensated Cirrhosis
Astrid Marot,Hélène Vandenbulcke,Jean-François Knebel,Christopher Doerig,Christophe Moreno,Pierre Deltenre +5 more
TL;DR: 1) Ajmera V, Perito ER, Bass NM, Terrault NA, Yates KP, Gill R, et al.
6
P1299 pearl-iii: 12 weeks of abt-450/r/267 + abt-333 achieved svr in >99% of 419 treatment-naive hcv genotype 1b-infected adults with or without ribavirin
Peter Ferenci,A. Nyberg,P. Enayati,David I. Bernstein,Yaacov Baruch,Florin Alexandru Caruntu,Vladimir Chulanov,Ewa Janczewska,Ziad Younes,Rui Tato Marinho,Giuliano Rizzardini,J. Gervain,Ramon Planas,Christophe Moreno,Wangang Xie,Dan Cohen,M. King,Thomas Podsadecki,K.R. Reddy +18 more
TL;DR: P1299 PEARL-III: 12 WEEKS of ABt-450/R/267 + ABT-333 ACHIEVED SVR in >99% of 419 TREATMENT-NAIVE HCV GENOTYPE 1B-INFECTED ADULTS with or without RIBAVIRIN P.Ferenci, A.R.
6
Association of PNPLA3 (rs738409 C>G) with liver damage in liver diseases: one step closer to personalized medicine?
TL;DR: This research presents a novel probabilistic approach to evaluate the immune response to PNPLA3 in patients with liver damage in liver diseases using a novel and scalable approach called “cell reprograming”.
6